InNexus Biotechnology Inc. Develops New Psoriasis Product Based on Its Skin Permeating Antibody Technology

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX.V: IXS) (www.ixsbio.com), a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the development of a new psoriasis product based on its proprietary dermal permeating Transmab™ technology.

MORE ON THIS TOPIC